ETF Explainer: ARKK

ARK’s actively managed fund broadly focused on disruptive innovation has exceled lately.

Reviewed by: Heather Bell
Edited by: Heather Bell
ARK Innovation ETF

Each month, we look at an ETF selected by based on its performance and importance to investors. This month, we consider the performance of the $5 billion ARK Innovation ETF (ARKK), which has been one of the best-performing ETFs of 2020. All the companies mentioned below are holdings in ARKK, unless otherwise noted (*).



For a larger view, please click on the image above.


AUG 5 Digital payments company Square falls sharply over the course of two trading days after a disappointing second-quarter earnings report and lowered guidance for the third quarter.

SEP 11 Genome sequencing firm Illumina sees its share price boosted after the U.K. announces a $250 million genome research project that will rely on Illumina’s technology.

NOV 7 Roku reports its third-quarter results. Although it exceeded revenue expectations, the company’s loss for the quarter drove its share price down by nearly 15% in after-hours trading.

FEB 4 Tesla sees its stock price increase 36% to reach a new high as the head of Baron Capital* suggests the carmaker could see $1 trillion in revenue in 10 years.

MAY 11 CRISPR Therapeutics’ stock price jumps 15% in two days after the FDA awards the company’s blood disease treatment CTX001 the designation “regenerative medicine advanced therapy.”

JUN 22 Medical genetic testing company Invitae announces it will acquire another genetic testing company, ArcherDX,* in a $1.4 billion deal, boosting the former’s share price significantly.

Source: Bloomberg; data for 6/30/2019-6/30/2020

Heather Bell is a former managing editor of She has also held editorial positions at Dow Jones Indexes and Lehman Brothers. Bell is a graduate of Dartmouth college and resides in the Denver area with her two dogs.